Open an account

Cardiff Oncology

CRDF · NASDAQ

$0.9315+$0.0458 (+5.17%)TodayMarket closed ·
Prev close $0.8857

CRDF analyst rating

HoldConsensus of 5 analysts over the last 12 months. 40% rate it a buy.
  • Strong buy0
  • Buy2
  • Hold3
  • Underperform0
  • Sell0

12-month price target · 7 analysts

Average $7.45 (+699.4% upside)

Low
$2.02
Now
$0.9315
High
$12.60

Upgrades and downgrades

The latest rating actions, newest first

CRDF analyst upgrades, downgrades and rating actions
FirmDateActionRating
HC Wainwright & Co.Sep 15, 2026UpgradeNeutral → Buy
William BlairAug 12, 2026DowngradeOutperform → Market Perform
Craig-HallumJun 3, 2026DowngradeBuy → Hold
TD CowenJun 1, 2026DowngradeBuy → Hold
HC Wainwright & Co.Jun 1, 2026DowngradeBuy → Neutral
Piper SandlerFeb 25, 2026MaintainsOverweight
HC Wainwright & Co.Jan 28, 2026MaintainsBuy

The case for and against

Updated Oct 15, 2026

Bull case

Cardiff Oncology is supported by a de-risking settlement with Nerviano that resolves all outstanding disputes over onvansertib’s global rights, removing a meaningful legal overhang for its lead PLK1 inhibitor. The amended 2017 Exclusive License Agreement adds stronger exclusivity protections, clearer governance, and revised economic terms tied to annual net sales, upcoming Phase 3 development, and potential transaction proceeds, which should better align incentives as the program advances. Fundamentally, the company’s appeal rests on onvansertib’s clinical promise in RAS-mutated metastatic colorectal cancer and other PLK1-driven tumors, targeting a large underserved population with high unmet need.

Bear case

Cardiff Oncology is a highly speculative clinical-stage biotech whose valuation depends heavily on onvansertib, yet the assigned probability of launch in 1L KRAS/NRAS+ mCRC is only 25%, underscoring a limited chance of commercial success. The investment case is further weakened by substantial execution and legal risk, including negative or delayed CRDF-004 data, setbacks in pivotal development, failure to obtain approval, and a potentially damaging license dispute with Nerviano that could disrupt access to development data and regulatory communications. Even under a DCF framework using an 11% discount rate and $848M estimated firm value, the outlook remains negative because near- to medium-term dilution risk and uncertain market penetration leave the equity highly vulnerable to adverse clinical or legal outcomes.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.